Every 10-Q that Savara Inc. (SVRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SVRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SVRA filings page.
Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, reported larger losses as it advances MOLBREEVI, its inhaled GM-CSF for autoimmune pulmonary alveolar proteinosis, toward potential approval. The company has no product revenue and remains pre-commercial.
For the three months ended June 30, 2026, Savara recorded a net loss of $40.2 million compared with $30.4 million a year earlier, driven by higher research and development and sharply higher general and administrative expenses as it builds commercial infrastructure. For the first half of 2026, the net loss was $77.5 million versus $57.0 million in 2025.
As of June 30, 2026, Savara held $41.8 million in cash and cash equivalents and $131.2 million in short-term investments, with long‑term debt of $30.1 million under a Hercules loan facility of up to $105 million. Management expects continued significant spending on development, regulatory, and commercialization activities and may seek additional capital over time.
Savara Inc. reported a net loss of $37.3M for the quarter ended March 31, 2026, wider than $26.6M a year earlier, driven by higher research and development and stock-based compensation. R&D expenses rose to $23.4M and general and administrative costs to $15.6M.
The company ended the quarter with $38.8M in cash and cash equivalents and $164.0M in short-term investments, supporting continued development of MOLBREEVI for autoimmune PAP. The FDA has filed the Biologics License Application, granted Priority Review, and extended the PDUFA date to November 22, 2026, while EMA and MHRA have validated marketing applications in Europe and the U.K.
Savara Inc. reported widening losses as it advances its sole product candidate, MOLBREEVI, an inhaled GM-CSF for autoimmune pulmonary alveolar proteinosis. Net loss was $30.4 million for the quarter and $57.0 million for the six months, up from $22.2 million and $42.6 million a year earlier, driven by higher research-and-development and commercial-preparation costs.
The company holds $17.4 million in cash and $129.0 million in short-term investments (total ~$146.4 million) and states this is sufficient to fund operations for at least the next 12 months. Savara received an FDA Refusal to File for its BLA but says the RTF raised CMC information requests only, not safety or efficacy; the company plans a December resubmission and will request Priority Review. Savara has a $200 million Hercules term loan facility with an initial $30 million draw, conditional future tranches tied to regulatory and revenue milestones and covenanted cash requirements that could restrict liquidity.